As Algeta's sibling, can Nordic Nanovector find the same success?
This article was originally published in Scrip
Executive Summary
Privately held cancer drug developer Nordic Nanovector – a spin-out company from the same founders who built Xofigo creator Algeta – is raising NOK150m ($25m) through a private placement of shares in order to progress development of its early-stage-blood cancer radio-immunotherapy, Betalutin. The CEO told Scrip that if all goes well, the company hopes to find a strategic partner and launch an IPO next year. However, there is a lot still to prove.